Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $47.40
Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) have received a consensus recommendation of “Buy” from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock […]
More Stories
Lynch & Associates IN Decreases Stake in Walmart Inc. (NYSE:WMT)
Lynch & Associates IN decreased its position in Walmart Inc. (NYSE:WMT – Free Report) by 1.8% during the fourth quarter,...
Lynch & Associates IN Boosts Stake in Chevron Co. (NYSE:CVX)
Lynch & Associates IN grew its stake in shares of Chevron Co. (NYSE:CVX – Free Report) by 2.3% during the...
Lynch & Associates IN Sells 566 Shares of The Walt Disney Company (NYSE:DIS)
Lynch & Associates IN cut its holdings in The Walt Disney Company (NYSE:DIS – Free Report) by 1.7% during the...
RMR Wealth Builders Buys 141,469 Shares of Schwab US Large-Cap ETF (NYSEARCA:SCHX)
RMR Wealth Builders boosted its stake in shares of Schwab US Large-Cap ETF (NYSEARCA:SCHX – Free Report) by 1,507.9% during...
Trinity Financial Advisors LLC Takes $259,000 Position in Visa Inc. (NYSE:V)
Trinity Financial Advisors LLC acquired a new position in Visa Inc. (NYSE:V – Free Report) during the fourth quarter, according...
Tilia Fiduciary Partners Inc. Boosts Stake in Visa Inc. (NYSE:V)
Tilia Fiduciary Partners Inc. lifted its position in Visa Inc. (NYSE:V – Free Report) by 3.5% in the fourth quarter,...